Optum vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
UnitedHealth Group (NYSE: UNH) health services at $226B revenue combining Optum Health clinics, Optum Rx PBM for 65M+, and Change Healthcare analytics; largest US health services company competing with CVS/Caremark.
About
Optum is the health services subsidiary of UnitedHealth Group (NYSE: UNH) — one of the world's largest companies with $400 billion in annual revenue — operating Optum Health (care delivery: primary care clinics, urgent care, surgical centers), Optum Rx (pharmacy benefit management: managing drug benefits for 65+ million people), and Optum Insight (health data analytics, technology, and consulting for health plans, providers, and government). With $226 billion in annual revenue in its own right (making Optum larger than most standalone health companies), Optum generates approximately 50% of UnitedHealth Group's total revenue and is the largest health services company in the world.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.